Corporate Strategy Update
In Q3, we closed a Capital Raise for our expansion plans that includes a strategic pathway to maturing into a general pharmaceutical manufacturer:
- New site expansion focussed on generic pharmaceutical finished medicines containing cannabinoids
- Drug Master File development, submissions, and regulatory approval
- Clinical trials
- International vertical integration into Germany and the UK
- Expanded commercialization of new technologies for our new product development pipeline
- Audits to obtain EU GMP Part 1 and Brasilian ANVISA approval
We are excited to share the progress around the developments towards the end of the year.
New Members
We have continued our growth, and as of September 2024, we have a full-time staff of 48 who have committed themselves to GES Labs’ vision. We also welcome new team leaders with years of global pharmaceutical experience, bringing mature growth into our Quality Management System (QMS) as we scale our supply chain to meet our clients’ demands on time and compliantly.
Roxanne Potgieter – Head of Quality
Roxanne joins with 15+ years of pharmaceutical manufacturing expertise. Having experience as Production Manager, Technical Expert, QA Pharmacist, QA Manager, Responsible Pharmacist, and Divisional QA leadership roles. She now leads our quality departments, bringing a strong international experience base to scale our business into the Future. She has worked at global and domestic successful pharmaceutical enterprises including Pharma Dynamics (a subsidiary of Lupin Ltd), Environ, Pharmaceutical Enterprises, NSF-CMi Africa, and ATP Manufacturing.
Monique Julius – Quality Assurance Manager
Monique joins with 15+ years of pharmaceutical manufacturing expertise. Having experience as a Distribution Pharmacist, Regulatory Manager, Responsible Pharmacist, Quality Assurance Executive, and QA Manager roles. She now together with Roxanne, provides QA support, mentorship, and leadership to our QA and QC teams. She has worked at strong pharmaceutical companies such as Barrs Pharmaceuticals, Opus Pharmaceuticals, Environ, The Biovac Institute, Vital Health Foods, and SekPharma.
We have a strong commitment to quality assurance, and we cannot wait to continue building our various custom systems that are quality-based and supply chain-focussed ensuring on-time, compliant delivery of our manufactured products globally.
We also have the following new team members joining us:
- Saziso Gobeni (QC Team)
- Kyle Scheepers (Production)
- Vishal Magan (Engineering Technical Team)
- Teri-Lee Homes (Production)
- Tylo Hunter (Engineering Technical Team)
Expansion, & Optimization
As we continue to re-invest in our vision and growth, we completed a successful expansion plan that will allow us to commercialize our research and development pipeline.
To date, we have expanded in the following areas this year, which have been qualified and commercially operational:
- Doubled cryo-ethanol extraction capacity
- Quadrupled our wiped film distillation technologies
- There is a tenfold increase in our ability to formulate MCT-cannabinoid formulations
This expansion and optimization have led to some operational savings from an economies of scale perspective and we decided to pass on those savings into our value chain, giving our partners immediate working capital saving and their current product lines. These enhancements in our operations led to a 25% reduction in our manufacturing costs surrounding our cryo-ethanol production costs.
We are also expanding our business with a new site build. We will employ a two-strategic facility build-out. Our existing facility, GES Labs, will be focused on unlicensed medicine production supporting patients globally where specialized, and personalized medicines have to be considered.
New Product Development
Our research and development department together with our production department has been successful in bringing forward a high-quality, large-scale solventless production line leading to our – ultra full-spectrum medical cannabis products.
More info: https://www.linkedin.com/pulse/pioneering-solventless-production-geslabs-cvjae/
This new product development has led to bringing in new equipment to put together new product categories in:
- Inhalation cartridges
- Inhalation concentrate formats
- Full-spectrum MCT-Rosin-THC oils
- Pastilles-Rosin
- Live resin inhalation products
- THC-A manufacturing and standardized THC API
Our new product development strategy is running full steam ahead, and we expect a highly innovative pipeline, to which our existing partners will thrive in the coming months. Part of our expansion later this year, includes the development of a state-of-the-art research and development dedicated laboratory, fitted with world-class technologies on a pilot scale, ability to commercialize at record time.
We are committed as always to these values
- Quality products
- Innovative solutions
- High quality of service offering
- A product offering, that is current, in-demand, and sustainable
